A Retrospective Study to Compare Biomarker Expression of Exosomes Derived From Peripheral Blood and Primary Lung Cancer Drainage Pulmonary Blood in Lung Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Korea University Guro Hospital
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Comparative analysis of cancer marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies.
This study is a retrospective blood sample obtained and prospectively comparative analysis of various biomarkers (cancer markers, and exosome markers) derived from peripheral blood and pulmonary venous blood from patients who underwent lung cancer surgery.
And treatment monitoring using biomarkers compare with peripheral and pulmonary blood.
Investigators
Hyun Koo Kim
Professor
Korea University Guro Hospital
Eligibility Criteria
Inclusion Criteria
- •Adults with Korean nationality
- •Patients who did not receive neoadjuvant therapy before surgery
- •Patients not diagnosed with any other cancer before surgery
- •Patients who agreed to the consent form for a donation of human materials during surgery
Exclusion Criteria
- •Patients who do not meet the inclusion criteria
Outcomes
Primary Outcomes
Comparative analysis of cancer marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein
Time Frame: 2020 ~ 2025
1. Comparative analysis of CEA and lung cancer-specific exosome marker concentrations in peripheral blood and pulmonary blood using ELISA assay 2. Characterization of exosomes using western blot, NTA, and TEM analysis
Diagnostic analysis of lung cancer-specific exosome marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein
Time Frame: 2020 ~ 2025
1) Evaluation of the clinical usefulness of lung cancer diagnosis using lung cancer-specific exosome markers in peripheral vein blood and primary lung cancer outflow pulmonary vein-derived blood.
Secondary Outcomes
- Evaluation of lung cancer treatment monitoring using lung cancer-specific exosome biomarkers(2020 ~ 2025)